Andrews P.I., Dicter M.A., Bercovic S.F. et al. Plasmapheresis in Rasmussen’s encephalitis // Neurology. – 1995. – Vol. 46, № 1. - P. 242-246.
Anlar B., Yimaz V., Saruhan-Direskeneli G. Long remission in muscle-specific kinase antibody-positive juvenile myasthenia // Pediatr. Neurol. – 2009. – Vol. 40, № 6. – P. 455-456.Applebee A., Panitch H. Early stege and ling term treatment of multiple sclerosis with interferon-β // Biologics. – 2009. – № 3. – P. 257-271.
Assessment of plasmapheresis. Report of the therapeutics and technology assessment subcommittee of the AMERICAN Academy of neurology // Neurology. – 1996. – Vol. 47, № 3. – P. 840-843.
Batocchi A.P., Evoli A., Di Schino C., Tonali P. Therapeutic apheresis in myasthenia gravis // Ther. Apher. – 2000. – Vol. 4, № 4. – P. 275-279.
Bell C., Graham J., Earnshaw S. et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data // J. Manag. Care Pharm. – 2007. – Vol. 13, № 3. – P. 245-261.
Ben David Y., Warner E., Levitan M. et al. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis // Cancer. – 1996. – Vol. 78, № 10. – P. 2153-2156.
Benkler M., Agmon-Levin N., Shoenfeld Y. Int. J. Neurol. – 2009. – Vol. 12, № 12. – P. 2133-2143.
Bernard C.C.A., Johns T.G., Slavin A. et al. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis // J. Mol. Med. - 1997. - Vol. 75, № 2. - P. 77-88.
Beyreuther K., Masters C.L. The ins and outs of amyloid- // Nature. – 1997. – Vol. 389, № 6652. – P. 677-678/
Boada M., Ortiz P., Anaya F. et al. Amyloid-targeted therapeutics in Alzheimer’s disease: use of human albumin in plasmaexchange as a novel approach for Abeta mobilization // Drug News Perspect. – 2009. – Vol. 22, № 6. – P. 325-339.
Boada-Povira M. Human albumin Grifols 5% in plasmapheresis: a new therapy involving beta-amyloid mobilization in Alzheimer’s disease // Rev. Neurol. – 2010. – Vol. 50, Suppl. 5. – P. S9-18.
Bonnan M., Valentino R., Olindo S. et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder // Mult. Scler. – 2009. – Vol. 15, № 4. – P. 487-492.
Bonnan M., Cabre P. Plasma exchange in severe attacks of neuromyelitis optica // Mult. Scler. Int. – 2012. – 2012: 787630.
Brannagan Th.H., Nagle K.L., Lange D.J., Rowland L.P. Complications of intravenous immune globulin treatment in neurologic disease // Neurology. - 1996. - Vol. 47, № 3. - P. 674-677.
Brannagan T.H. Current treatments of chronic immune-mediated demyelinating polyneuropathies // Muscle Nerve. – 2009. – Vol. 39, № 5. – P. 563-578.
Brashear H.R., Phillips L.H. Autoantibodies to GABAergic neurons and response to plasmapheresis in stiff-man syndrome // Neurology. - 1991. - Vol. 41, № 10. - P. 1588-1592.
Burwinkel M., Riemer C., Schwartz A. et al. Role of cytokines and chemokines in prion infections of the central nervous system // Int. J. Dev. Neurosci. – 2004. – Vol. 22, № 7. – P. 497-505.
Buzzigoli S.B., Genovese M., Lambelet P. et al. Plasmapheresis treatment in Gillain-Barré syndrome: potential benefit over intravenous immunoglobulin // Anaesth. Intensive Care. – 2010. – Vol. 38, № 2. – P. 387-389.
Castillo G., Ngo C., Cummings J. et al. Perlecan binds to the -amyloid proteins (A) of Alzheimer’s disease, accelerates A fibril formation, and maintains A fibril stability // J. Neurochem. – 1997. – Vol. 69, № 6. – P. 2452-2465.
Chiu H.C., Chen W.H., Yah J.H. Double filtration plasmapheresis in the treatment of inflammatory polyneyropathy // Ther. Apher. – 1997. – Vol. 1, № 2. – P. 183-186.
Clerico M., Rivorio C., Contessa G. et al. The therapy of multiple sclerosis with immune-modulating or immunosupressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews //Clin. Neurol. Neurosirg. – 2008. – Vol. 110, № 9. – P. 878-886.
Clifford D.B., De Luca A., Simpson D.M. et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases // Lancet Neurol. – 2010. – Vol. 9, № 4. – P. 438-446.
Chuang Y.C., Lee C.T., Chen J.B., Chee E.C. Experience in the treatment of myasthenia gravis with double filtration plasmapheresis // Chang Gung Med. J. – 2000. – Vol. 23, № 2. – P. 80-86.
Cortese I., Chaudhry V., So Y.T et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommitee of the American Academy of Neurology //Neurology. – 2011. – Vol. 76, №3. – P. 294-298.
Dada M.A., Kaplan A.A. Plasmapheres treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement // Ther. Apher. Dial. – 2004. – Vol. 8, № 5. – P.409-412.
Dalakas M.C. Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: present and future prospects // Ann. Neurol. - 1995. - Vol. 37, Suppl. 1. - P. S2-S13.
Dau P.C., Denis E.H. Plasmapheresis and immunosupressive drug therapy in the Eaton-Lambert syndrome // Ann. Neurol. - 1982. - Vol. 11, № 6. - P. 570-575.
De Lau L.M., Siepman D.A., Remmers M.J. et al. Acute disseminating encephalomyelitis following legionnairs disease // Arch. Neurol. – 2010. – Vol. 67, № 5. – P.623-626.
Dhand U.K. Clinical approach to the weak patient in the intensive care unit // Respir. Care. – 2-1-. – Vol. 51, № 9. – P. 1024-1040.
Dick P.J., Low P.A., Windebank A.J. et al. Plasma exchange in polyneuropathy associated worth monoclonal gammapathy of undetermined significance // N. Eng. J. Med. - 1991. - Vol. 325, № 21. - P. 1482-1486.
Dick P.J., Litchy W.J., Kratz K.M. et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy // Ann. Neurol. - 1994. - Vol. 36, № 6. - P. 838-845.
Dropcho E.J. Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options // Ann. Neurol. - 1995. - Vol. 37, Suppl. 1. - P. S102-S113.
El-Bawab H., Hajjar W., Rafay M. et al. Plasmapheresis before thymectomy in myasthenia gravis: routine versus selective protocols // Eur. J. Cardiovasc. Surg. – 2009. – Vol. 35, № 3. – P. 392-397.
El-Bayoumi M.A., El-Rafaey A.M., Abdelkader A.M. et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain-Barré syndrome: a randomized study // Crit. Care. – 2011. – Vol. 15, № 4. – P. R164.
Flanagan E.P., McKeon A., Lennon V.A. et al. Autoimmune dementia: clinical course and predictors of immunotherapy response // Mayo Clin. Proc. – 2010. – Vol. 85, № 10. – P. 881-897.
Fleury M.C., Tranchant C. Myasthenia gravis // Rev. Prat. – 2008. – Vol. 58, № 20. – P. 2217-2224.
Fogan L. Progressive encephalomyelitis with rigidity responsive to plasmapheresis and immunosupression // Ann. Neurol. - 1996. - Vol. 40, № 4, -- P. 451-453.
Fukazawa T., Kikuchi S., Sasaki H. et al. Antinuclear antibodies and the optic-spinal form of multiple sclerosis // J. Neurol. - 1997. - Vol. 244, № 8. - P. 483-488.
Gaidos P., Chevret S., Clair B. et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia Gravis // Ann. Neurol. - 1997. - Vol. 41, № 6. - P. 789-796.
Gambetti P., Parch P. Insomnia in prion diseases: sporadic and familial // New Engl. J. Med. - 1999. - Vol. 340, № 21. - P. 1675-1677.
Geschwind M.D., Tan KL.M., Lennon V.A. et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jalob disease // Arch. Neurol. – 2008. – Vol. 65, № 10. – P. 1341-1346.
Gold R., Schneider-Gold C. Current and future standarts in treatment of myasthenia gravis // Neurotherapeutics. – 2008. – Vol. 5, № 4. – P. 535-541.
Gold R., Hohlfeld R., Toyka K.V. Progress in the treatment of myasthenia gravis // Ther. Adv. Neurol. Disord. – 2008. – Vol. 1, № 2. – P. 36-51.
Gómez-Isla T., Wasco W., Pettingell W.P. A novel Presenilin-1 mutation: increase -amyloid and neurofibrillary changes // Ann. Neurol. - 1997. - Vol. 41, № 6. - P. 809-813.
Gorson K.C. An update on the management of chronic inflammatory demyelinating polyneuropathy // Ther. Adv. Neurol. Disord. – 2012. – Vol. 5, № 6. – P. 359-373.
Graf W.D., Katz J.S., Eder D.N. et al. Outcome in severe pediatric Guillain-Barré syndrome after immunotherapy or supportive care // Neurology. - 1994. - Vol, № 7. - P. 1494-1497.
Graus F., Vega F., Delatre J.Y. et al. Plasmapheresis and antineoplastic treatment CNS paraneoplastic syndrome with antineuronal autoantibodies // Neurology. - 1992. - Vol. 42, № 3. - P. 536-540.
Greenberg S.M., Hyman B.T. Cerebral amyloid angiopathy and apolipoptotein E: bad news to the good allele? // Ann. Neurol. - 1997. - Vol. 41, № 6. - P. 701-702.
Gwathmey K., Balogun R.A., Burns T. Neurologic indications for therapeutic plasma exchange: an apdate // J. Clin. Apher. – 2011. – Vol. 26, № 5. – P. 261-268.
Hagiwara H., Sakamoto S., Katsumata T., Katayama Y. Acute disseminated encephalomyelitis developed after Mycoplasma pneumoniae infection complicating subclinical measles infection // Intern. Med. – 2009. – Vol. 48, № 6. – P. 479-483.
Hanafusa N., Kondo Y., Suzuki M. et al. Double filtration plasmapheresis can decrease factor XIII activity // Ther. Apher. Dial. – 2007. – Vol.11, № 3. – P. 165-170.
Hao Q., Saida T., Yoshino H. et al. Anti-GalNAc-GD1a antibody-associated Guillain-Barré syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance // Ann. Neurol. – 1999. – Vol. 45, № 6. – P. 758-768.
Hashimoto H. Microscopic polyangiitis in systemic sclerosis // Int. J. Reumatol. – 2010, 2010: 148528.
Haupt W.F. Recent advances of therapeutic apheresis in Guillain-Barré syndrome // Ther. Apher. – 2000. – Vol. 4, № 4. – P. 271-274.
Hughes R.A., Wijdicks E.F., Barohn R. et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology // Neurology. – 2003. – Vol. 61, № 6. – P. 736-740.
Hughes R.A., Swan A.V., Raphaёl J.C. et al. Immunotherapy for Guillain-Barré syndrome: a systematic review // Brain. – 2007. – Vol. 130, Pt 9. – P. 2245-2257.
Hughes R.A.C. Give or take? Intravenous immunoglobulin or plasma exchange for Guillain-Barré syndrome // Crit. Care. – 2011. – Vol. 15, № 4. – P. 174.
Hund E.F., Fogel W., Krieger D. et al. Critical illness polyneuropathy: clinical findings and outcomes of a frequent cause of neuromuscular weaning failure // Crit. Car Med. – 1996. – Vol.24, № 8. – P. 1328-1333.
Iodice V., Kimpinski K., Vernini S. et al. Efficacy of immunotherapy in serpositive and seronegative putative autoimmune autonomic gangliopathy // Neurology. – 2009. – Vol. 72, № 23. – P. 2002-2008.
Jaben E.A., Pulido J.S., Pittick S. et al. The potential role of plasma exchange as treatment for bilateral diffuse uveal melanocytic proliferation: a report of two cases // J. Clin. Apher. – 2011. – Vol. 26, № 6. – P. 356-361.
Karim S., Majithia V. Devic’s syndrome as initial presentation of systemic lupus erythematosus // Am. J. Med. Sci. – 2009. – Vol. 338, № 3. – P. 245-247.
Kaynar L., Altuntas F., Aydoglu I. et al. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study // Transfus. Apher. Sci. – 2008. – Vol. 38, № 2. – P. 109-115.
Khatri B.O., McQuillen M.P., Hoffman R.G. Plasma exchange in chronic progressive multiple sclerosis. A long term study // Neurology. - 1991. - Vol. 41, № 4. - P. 409-414.
Kincaid J.C. Apheresis in treatment of the inflammatory demyelinating peripheral neuropathies // Ther. Apher. Dial. – 2002. – Vol. 6, № 1. – P. 53-56.
Koehler P.J., Kondstaal J. Lethal hypersensitivity myocarditis associated with the use of intravenous gammaglobulin for Guillain-Barré syndrome, in combination with phenitoin // Neurology. – 1996. – Vol. 243, № 4. – P. 366-367.
Köhler W., Bucka C., Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis // J. Clin. Apher.. – 2011. – Vol. 26, № 6. – P. 347-355.
Konishi T. [Plasmapheresis in patients with myasthenia gravis] // Nippon Rinsho. – 2008. – Vol. 66, № 6. – P. 1165-1171.
Kornberg A.J., Pertronk A. Chronic motor neuropathies: diagnosis, therapy, and pathogenesis // Ann. Neurol. - 1995. - Vol. 37, Suppl. 1. -S43-50.
Körner H., Riminton D.S., Stickland D.H. et al. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting // J. Exp. Med. - 1997. - Vol. 186, № 9. - P. - 1585-1590.
Keegan M., Pineda A.A., McClelland R.L. et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response // Neurology. – 2002. – Vol. 58, № 1. – P. 143-146.
Landtblom A.M., Lindval B., Ledin T., Berlin G. A case report of plasmapheresis treatment in a patient with paraneoplastic cerebellar degeneration and high anti-yo antibody titres // Ther. Apher. Dial. – 2008. – Vol. 12, № 1. – P. 82-85.
Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammapathy // Ann. Neurol. - 1995. - Vol. 37, Suppl. 1. - P. S32-42.
Leopold N.A., Bara-Jimenez W., Hallett M. Parkinsonism after a wasp sting. – 1999. – Vol. 14, № 1. – P. 122-127.
Levey A.I., Heilman C.J., Lah J.J.. Nash N.R. et al. Presenilin-1 protein expression in familial and sporadic Alzheimer’s disease // Ann. Neurol. - 1977. - Vol. 41, № 6. - P. 742-753.
Levis R.A., Selwa J.F., Lisak R.P. Myasthenia gravis: immunological mechanisms and immunotherapy // Ann. Neurol. - 1995. - Vol. 37, Suppl. 1. - P. S51-S62.
Leys K., Lang B., Johnston I., Newsom-Davis J. Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome // Ann. Neurol. - 1991. - Vol. 29, № 3. - P. 307-314.
Lin C.H., Jeng J.S., Yip P.K. Plasmapheresis in acute disseminated encephalomyelitis // J. Clin. Apher. – 2004. – Vol. 19, № 3. – P. 154-159.
Lindstrom J.M., Seybold M.E., Lenon V.A. et al. Antibody to acetylcholine receptor in myastenia gravis: prevalence, clinical correlates, and diagnostic value // Neurology. - 1998. - Vol. 51, № 4. - P. 933.
Liu J.F., Wang W.X., Xue J. et al. Comparing the autoantibody levels and clinical efficacy of double plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis //Ther. Apher. Dial. – 2010. – Vol. 14, № 2. – P. 153-160.
Lo Y.L. Clinical and immunological spectrum of the Miller Fisher syndrome // Muscle Nerve. – 2007. – Vol. 36, № 5. – P.615-627.
Lopate G., Parks B.J., Goldstein J.M. et al. Polyneuropathies associated with high titre antisulphatide antibodies: characteristics of patients with and without serum monoclonal proteins // J. Neurol. Neurosurg. Psychiatry. - 1997. - Vol. 62, № 6. - P. 581-585.
Madrid A., Gil-Peralta A., Gil-Néсig E. et al. Morvan’ s fibrillary chorea: remission after plasmapheresis // J. Neurol. - 1996. - Vol. 243, № 4. - P. 350-353.
Magaña S.M., Pittock S.J., Lennon V.A. et al. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease // Arch. Neurol. – 2009. – Vol. 66, № 8. – P. 964-966.
Magaña S.M., Keegan B.M., Weinshenker B.G. et al. Beneficial plasma exchange response in CNS inflammatory demyelination // Arch. Neurol. – 2011. – Vol. 68, № 7. – P. 870-878.
Majorga C., Luque G., Romero F. et al. Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta // Int. Arch. Allergy Immunol. – 1999. – Vol. 118, № 2-4. – P. 368-371.
Marin D.B., Breuer B., Marin M.L. et al. The relationship between apolipoprotein E, dementia, and vascular ilness // Atherosclerosis. - 1998. - Vol. 140, № 1. - P. 173-180.
Mastriani J.A., Nixon R., Layzer R. et al. Prion protein conformation in patients with sporadic fatal insomnia // New Engl. J. Med. - 1999. - Vol. 340, № 21. - P. 1630-1638.
Mattson M.P. Cellular actions of -amyloid precrusor protein and its soluble and fibrillogenic derivates // Physiol. Rev. - 1997. - Vol. 77, № 4. - P. 1081-1132.
McDaneld L.M., Fields J.D., Bourdette D.N., Bhardwaj A. Immunomodulatory therapies in neurologic critical care // Neurocrit. Care. – 2010. – Vol. 12, № 1. – P. 132-143.
Mecocci P., Polidori M.C., Ingegni T. et al. Oxidative damage to DNA in lymphocytes from AD patients // Neurology. – 1998. – Vol. 51, № 4. – P. 1014-1017.
Meena A.K., Khadikar S.V., Murthy J.M.K. Teatment guidelines for Guillain-Barré syndrome // Ann. Indian Acad. Neurol. – 2011. – Vol. 14, Suppl. 1. – P.S73-S81.
Mirza M.K., Pogoriler J., Paral K. et al. Adjunct therapeutic plasma exchange for anti-N-methyl-D-aspartate receptor antibody encephalitis: a case report and review of literature // J. Clin. Apher. – 2011. – Vol. 26, № 6. – P. 362-365.
Miyamoto K., Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica // Ther. Apher. Dial. – 2009. – Vol. 13, № 6. – P. 505-508.
Moll J.W.B., Hooijkaas H., van Goorbergh B.C.M. et al. Systemic and antineuronal autoantibodies in patients with paraneoplastic neurological disease // J. Neurol. - 1996. - Vol. 243, № 1. Р. 51-56.
Monahan A.J., Warren M., Carvey P.M. Neuroinflammation and peripheral infiltration in Parkinson’s disease: an autoimmune hypothesis // Cell. Transplant. – 2008. – Vol. 17, № 4. – P. 363-372.Myasthenia Gravis Clinical Group, Gajdos Ph., Chevret S. et al., Clinical trial of plasma exchenge and high-dose intravenous immunoglobulin im myasthenia gravis. – Ann. Neurol. – 1997. – Vol. 35, № 41. – P. 789-796.
Nachamkin I., Ung H., Moran A.P. et al. Ganglioside GM1 mimicry in Campilobacter strains from sporadic infections in the United States // J. Infect. Dis. – 1999. – Vol. 179, № 5. – P. 1183-1189.
Nakamura Y., Kawachi Y., Furuta J., Otsuka F. Sewere local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection // Eur. J. Dermatol. – 2008. – Vol. 18, № 5. – P. 579-582.
Netto A.B., Taly A.B., Kulkarni G.B. et al. Mortality in mechanically ventilated patients of Guillain-Barré syndrome // An. Indian Acad. Neurol. – 2011. – Vol. 14, № 4. – P. 262-268.
Nowak R.J. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study // Ther. Adv. Neurol. Disord. – 2011. – Vol. 4, № 5. – P. 259-266.
Offen D., Halevi S., Mosberg R. et al. Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels // Neurology. - 1998. - Vol. 51, № 4. - P. 1100-1103.
Ohji S., Nomura K. [The indication of steroid therapy and apheresis therapy for multiple sclerosis] // Nippon. Rinsho. – 2008. – Vol. 66, № 6. – P. 1127-1132.
Okushin H., Morii K., Uesaka K., Yasa S. Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C // World J. Hepatol. – 2010. – Vol. 2, № 6. – P. 226-232.
Papazian O., Alfonso I. Juvenile myasthenia gravis // Medicina (B Aires). – 2009. – Vol. 69, № 1. – P. 71-83.
Park Y.-E., Yook J.-W., Kim D.-S. A case of Lewis-Sumner syndrome showing dramatic improvement after plasma exchange // J. Korean Med. Sci. – 2010. – Vol. 25, № 7. – P. 1101-1104.
Perera N.J., Lewis B., Tran H. et al. Refsum’s disease-use of the intestinal lipase inhibitor, Orlistat, as novel therapeutic approach to a complex disorder // J. Obes. – 2011. – pii: 482021.
Pestronk A., Choki R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent lincage of Gm1 to ELISA plates // Neurology. - 1997. - Vol. 49, № 5. - P. 1289-1291.
Pham H.P., Daniel-Johnos J.A., Stotler B.A. et al. Therapeutic plasma exchange for the treatment of anti-NMDA receptor encephalitis // J. Clin. Apher. – 2011. – Vol. 26, № 6. – P. 320-325.
Pittayanon R., Treepraertsuk S., Phanthumchinda K. Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn Memorial Hospital // J. Med. Assoc. Thai. – 2009. – Vol. 92, № 4. – P. 478-482.
Plasma Exchange / Sandoglobulin Gillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatment in Guillain-Barré syndrome // Lancet. - 1997. - Vol. 349, № 9047. - P. 225-230.
Plosker D.L. Interferon-β-1b: a review of its use in multiple sclerosis // CNS Drugs. – 2011. – Vol. 25, № 1. – P. 67-88.
Pula J.H., MacDonald C.J. Current options for the treatment of optic neuritis // Clin. Opthalmol. – 2012. – № 6. – P. 1211-1223.
Rabie M., Nevo Y. Childhood acute and chronic immune-mediated polyradiculoneuropathies // Eur. J. Paediatr. Neurol. – 2009. – Vol. 13, № 3. – P. 209-218.
Rafael G.C., Chevret S. Rational therapy of Guillain-Barré syndrome // Lancet. -1998. - Vol. 351, № 9104. -P. 753.
Ramunni A., De Robertis F., Brescia P. et al. A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis // Ther. Apher. Dial. – 2008. – Vol. 12, № 3. – P. 250-254.
Ric G.P.A., Paszner B., Oger J. et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon -1b // Neurology. – 1999. – Vol. 52, № 6. – P. 1277-1279.
Riemer C., Gültner S., Heise I. et al. Neuroinflammation in prion diseases: concepts and targets for therapeutic intervention // 2009. – Vol. 8, № 5. – P. 329-341.
Roca I., Cuberas-Borros G. Neuroimaging in Alzheimer’s disease: findings in plasmapheresis with albumin // Rev. Neurol. – 2010. – Vol. 50, Suppl. 5. – P. S19-22.
Rogalewski A., Kraus J., Hasselblatt M. et al. Improvement of advanced postvaccinal demyelinating encephalitis due to plasmapheresis // Neuropsychiatr. Dis. Treat. – 2007. – Vol. 3, № 6. – P. 987-991.
Sanders D.B. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediates mechanisms, and update on therapies // Ann. Neurol. - 1995. - Vol. 37, Suppl. 1. - P. S63-S73.
Sanford M., Lyseng-Williamson K.A. Subcutaneous recombinant interferon-β-1a (Rebif): a review of its use in the treatment of relapsing multiple sclerosis // Drugs. – 2011. – Vol. 71, № 14. – P. 1865-1891.